Secondary Malignancies After Hematopoietic Cell Transplantation

Bhatia, Smita; Bhatia, Smita

doi:10.1002/9780470987070.ch70

Cited by 5 publications

(13 citation statements)

References 167 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The median time to development is 12-24 months after SCT. 1,[4][5][6] The Risk factors include: 4 (a) pre-transplantation therapy with alkylating agents, topoisomerase II inhibitors and radiation therapy; (b) use of peripheral blood as source of stem cells; (c) use of TBI in conditioning. 1 The prognosis is very poor with a median survival of 6 months.…”

Section: Myelodysplasia and Amlmentioning

confidence: 99%

“…The incidence probability is about 1% in allogeneic transplants, 1,4,8,9 but is much higher (until 14%) after non-HLA-identical, T-cell-depleted bone marrow transplants in which Campath IG and anti-LFA 1 were given. 10 Risk factors associated with higher probability of development of BCLD are: 4,8 (a) in vitro T-cell depletion; (b) unrelated or HLAmismatched related donor, (c) moderate or extensive chronic GVHD; (d) use of ATG or anti-CD3; (e) use of TBI in the preparative regimen; (f) primary immunodeficiency.…”

Section: Bcldmentioning

confidence: 99%

“…1 The prognosis is very poor with a median survival of 6 months. 4 Complete remission is attained in only 35-40% and patients receiving an allogeneic SCT have a very high rate of nonrelapse mortality. 7 Nevertheless, if an appropriate donor is available, patients without a high peripheral blast count and with unfavorable cytogenetics should be considered for a prompt transplantation.…”

Section: Myelodysplasia and Amlmentioning

confidence: 99%

“…The large majority of lymphoproliferative disorders are of B-cell origen and usually develop within the first 6 months after SCT. 4 Clinically and morphologically BCLD is a heterogeneous group of diseases.…”

Section: Bcldmentioning

confidence: 99%

“…[1][2][3][4] The main factors for developing secondary malignancies are intensive cytotoxic conditioning therapy and previous chemotherapy and radiotherapy, immunosuppression in allogeneic transplants, infection with viruses such as EBV, HBV and HCV and genetic factors in certain diseases (Fanconi anemia). 4 Secondary malignancies are commonly classified in three groups: (1) myelodysplasia (MDS) and acute myeloid leukemia (AML); (2) B-cell post-transplant lymphoproliferative disorders (BCLD) and (3) solid tumors (ST).…”

Section: Secondary Malignanciesmentioning

confidence: 99%

See 4 more Smart Citations

Secondary malignancies and quality of life after stem cell transplantation

Ortega

Olivé

Heredia

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Malignant diseases (MD) occurring after stem cell transplantation (SCT) are of particular concern as increasing number of patients survive and remain free of their original disease. The cumulative incidence at 15 years is 10-12%. The B-cell proliferative disorders (BCLP) are the most common MD in the first year after SCT; the incidence probability is 1% in allogeneic transplants but is much higher (until 14%) after HLAidentical, T-cell-depleted SCT in which Campath 1G or ATG are given. BCLP develop because of reactivation of the EBV and a depressed cellular immunity. Prediction of risk of BCLP can be made by frequent monitoring of EBV load in patients with risk factors. The most effective therapies are the early administration of anti-CD20 monoclonal antibody and adoptive immunotherapy with in vitro generated EBV-specific cytotoxic T cells. Myelodysplasia and acute myeloid leukemia with very poor prognosis have been described in 4-18% of patients with non-Hodgkin lymphoma and Hodgkin disease, 12-24 months after autologous SCT. The risk of development of solid tumors increases over time and the cumulative incidence among children who underwent an SCT at less than 10 years of age is 6-11% at 15 years. There are few studies evaluating quality of life (QOL) in children and adolescents who had received an SCT. The findings of these studies can be summarized as follows: (a) The majority of long survivors enjoy good QOL and return successfully to school or work.

show abstract

Section: Myelodysplasia and Amlmentioning

confidence: 99%

Section: Bcldmentioning

confidence: 99%

Section: Myelodysplasia and Amlmentioning

confidence: 99%

Section: Bcldmentioning

confidence: 99%

Section: Secondary Malignanciesmentioning

confidence: 99%

See 3 more Smart Citations

Secondary malignancies and quality of life after stem cell transplantation

Ortega

Olivé

Heredia

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

Advanced secondary lung adenocarcinoma, ALK mutated, from treatment of childhood osteopetrosis

Moffat

Davidson

Gregg

2022

Pediatric Blood & Cancer

View full text Add to dashboard Cite

Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up

et al. 2005

View full text Add to dashboard Cite

SummaryA total of 81 severe aplastic anaemia patients, aged 2-63 years, received human leucocyte antigen-matched related marrow grafts after cyclophosphamide + antithymocyte globulin followed by postgrafting methotrexate + ciclosporin. Median follow-up was 9AE2 years. Ninety-six per cent of patients had sustained engraftment, 24% developed acute graft-versushost disease (GVHD), grade II in all but two patients, and 26% developed chronic GVHD; all surviving patients eventually responded to immunosuppressive therapy. Six patients developed cancer: one fatal lymphoma and five carcinomas (all five patients are now free of cancer). Survival was 88%. The regimen appeared well tolerated and effective in heavily pretreated patients with aplastic anaemia.

show abstract

Secondary Malignancies After Hematopoietic Cell Transplantation

Cited by 5 publications

References 167 publications

Secondary malignancies and quality of life after stem cell transplantation

Secondary malignancies and quality of life after stem cell transplantation

Advanced secondary lung adenocarcinoma, ALK mutated, from treatment of childhood osteopetrosis

Cyclophosphamide and antithymocyte globulin as a conditioning regimen for allogeneic marrow transplantation in patients with aplastic anaemia: a long‐term follow‐up

Contact Info

Product

Resources

About